🇺🇸 FDA
Pipeline program

TAK-279

TAK-279-PsO-3005

Phase 3 small_molecule active

Quick answer

TAK-279 for Generalized Pustular Psoriasis is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Generalized Pustular Psoriasis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials